Immunai and Boehringer partner to identify T-cell targets
Pharmaceutical Business Review
The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both parties agree.
pharminent
June 26, 2026 (Last updated: June 26, 2026)
Pharmaceutical Business Review
The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both parties agree.
